50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer Disease, Early Onset
Conditions
Alzheimer Disease, Early Onset, Alzheimer Disease
Trial Timeline
Aug 18, 2017 → Mar 27, 2018
NCT ID
NCT03784300About 50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125 is a phase 1 stage product being developed by Cassava Sciences for Alzheimer Disease, Early Onset. The current trial status is completed. This product is registered under clinical trial identifier NCT03784300. Target conditions include Alzheimer Disease, Early Onset, Alzheimer Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03784300 | Phase 1 | Completed |
Competing Products
20 competing products in Alzheimer Disease, Early Onset
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 44 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| Zagotenemab + Placebo | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 77 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 + Placebo | Alector | Phase 2 | 44 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 | Alector | Phase 2 | 44 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| donanemab | Eli Lilly | Phase 2 | 52 |
| ATH-1017 | LeonaBio | Phase 2/3 | 57 |
| ATH-1017 + Placebo | LeonaBio | Phase 2/3 | 57 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| NDX-1017 + Placebo | LeonaBio | Phase 1 | 25 |
| simufilam | Cassava Sciences | Phase 2 | 44 |
| Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tablet | Cassava Sciences | Phase 2 | 44 |